Does afatinib plus bevacizumab combination therapy induce positive conversion of T790M in previously-negative patients?

Third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are markedly effective for T790M-positive patients. To confer their clinical benefit to more patients, a novel therapy to induce positive conversion in T790M-negative patients may be possible. We retrospective...

Descripción completa

Detalles Bibliográficos
Autores principales: Hata, Akito, Katakami, Nobuyuki, Kaji, Reiko, Yokoyama, Toshihide, Kaneda, Toshihiko, Tamiya, Motohiro, Inoue, Takako, Kimura, Hiromi, Yano, Yukihiro, Tamura, Daisuke, Morita, Satoshi, Negoro, Shunichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6205165/
https://www.ncbi.nlm.nih.gov/pubmed/30410675
http://dx.doi.org/10.18632/oncotarget.26192

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6205165/
https://www.ncbi.nlm.nih.gov/pubmed/30410675
http://dx.doi.org/10.18632/oncotarget.26192

Ejemplares similares